It is time for the world to take COPD seriously: a statement from the GOLD board of directors

David M.G. Halpin1, Bartolome R. Celli2, Gerard J. Criner3, Peter Frith4, M. Victorina López Varela5, Sundeep Salvi6, Claus F. Vogelmeier7, Ronchang Chen8, Kevin Mortimer9, Maria Montes de Oca10, Zaurbek Aisanov11, Daniel Obaseki12, Rebecca Decker13 and Alvar Agusti14

Affiliations: 1University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK. 2Brigham and Women’s Hospital, Pulmonary Division, Boston, MA, USA. 3Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 4Flinders University College of Medicine and Public Health, Adelaide, Australia. 5Cátedra de Neumología, Facultad de Medicina, Universidad de la República Hospital Maciel, Montevideo, Uruguay. 6Chest Research Foundation, Pune, India. 7Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany. 8Guangzhou Institute of Respiratory Disease, State Key Lab of Respiratory Disease and National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 9Liverpool School of Tropical Medicine, Liverpool, UK. 10Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela. 11Dept of Pulmonology, N.I. Pirogov Russian State National Research Medical University, Healthcare Ministry of Russia, Moscow, Russia. 12Dept of Medicine, Obafemi Awolowo University, Ile-Ife, Nigeria. 13Program Director, Global Initiative for Chronic Obstructive Lung Disease. 14Institut Respiratori, Hospital Clinic, IDIBAPS Universitat de Barcelona, CIBER Enfermedades Respiratorias, Barcelona, Spain.

Correspondence: David M.G. Halpin, University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK. E-mail: d.m.g.halpin@ex.ac.uk

@ERSpublications

We must work together to prevent the development of COPD by reducing exposure to risk factors, to ensure the diagnosis is made as early as possible and to ensure all patients around the world receive effective therapy http://bit.ly/2WDUPMp


This single-page version can be shared freely online.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the world and it is thought that one in 10 of the adult global population have the disease [1]. Despite this, COPD has not received the level of attention it requires by Ministries of Health and health services, particularly in low- and middle-income countries (LMIC), where most of the people with this disease live and where there is limited access to spirometry to confirm the diagnosis, little effective therapy and minimal public health policy on prevention. In 2012 the World Health Assembly endorsed the “25 by 25 goal”, focusing on reducing premature deaths from noncommunicable disease (NCDs) by 25% by the year 2025 [2], but while the third United Nations (UN) high-level meeting on NCDs in September 2018 acknowledged that “action to realize the commitments made for the prevention and control of noncommunicable diseases is inadequate” many felt the political declaration lacked ambition and was a missed opportunity to address the global NCD epidemic. As COPD is a highly prevalent NCD, is the third most common cause of premature death and is highly preventable we, the Board of Directors of the Global Initiative for Chronic
Obstructive Lung Disease (GOLD), are especially concerned that the disease has not been taken seriously enough by the UN/World Health Organization (WHO): not enough is being done to address the increasing prevalence, morbidity and mortality caused by COPD and there is no coordinated strategy to encourage countries to prioritise and resource its prevention and management.